| Ytd | 26.84% | |
| 1y | 137.88% |
| Open | 6.47 | Prev Close | 6.50 | Low | 6.30 | High | 6.64 | Mkt Cap | 667.28M |
| Vol | 419.14K | Avg Vol | 1.81M | EPS | -1.12 | P/E | -5.80 | Forward P/E | -3.30 |
| Beta | 2.21 | Short Ratio | 23.98 | Inst. Own | 59.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 5.60 | 200-d Avg | 4.65 | 1yr Est | 16.44 |
Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) was up 6.5% during mid-day trading on F
US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales
Achieve Life Sciences NASDAQ: ACHV held its 2026 Annual Meeting of Stockholders virtually, with Chie
The last months were eventful for Achieve Life Sciences, sending the stock strongly down, but later
Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmace
SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, In
Achieve Life Sciences remains a cytisinicline story, with very positive smoking-cessation data. This
Achieve Life Sciences Inc. (NASDAQ:ACHV) on Monday received a Complete Response Letter (CRL) from th
FDA rejects Achieve Life Sciences application for cytisinicline tied to manufacturing issues, with N
HC Wainwright & Co. analyst Brandon Folkes reiterates Achieve Life Sciences (NASDAQ:ACHV) wit
The U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat
Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmace
CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficien
Retail investors talked up five hot stocks this week (June 15 to June 18) on X and Reddit's r/Wa
Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Compa
ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation N
Achieve Life Sciences (ACHV) is downgraded to 'Hold' due to anticipated CRL of cytisinicline for smo
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Achieve Life Sciences NASDAQ: ACHV used its first-quarter 2026 earnings call to outline a transition
Christopher Martin joins the Board of Directors, with Mark Zappia and Jim Willis joining as Senior V
Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in M
SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc
Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) has been assigned an average recommenda
Canaccord Genuity analyst Gary Nachman initiates coverage on Achieve Life Sciences (NASDAQ:ACHV)
Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Fina
Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Fin
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Withi
HC Wainwright & Co. analyst Brandon Folkes reiterates Achieve Life Sciences (NASDAQ:ACHV) wit
Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing CapabilityCompany Re
Achieve Life Sciences taps Adare for cytisinicline manufacturing as stock falls; reports wider losse
HC Wainwright & Co. analyst Brandon Folkes reiterates Achieve Life Sciences (NASDAQ:ACHV) wit
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.28) per share which missed the
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 12
On Tuesday, 838 companies hit new 52-week lows.
Monday saw 825 companies set new 52-week lows.
On Wednesday, 340 stocks hit new 52-week lows.
On Tuesday, 250 stocks hit new 52-week lows.
During Tuesday's session, 539 stocks hit new 52-week lows.